Clinical trials
Phase 3 Postoperative Complications trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
14 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2016 | 2 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 14 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Università degli Studi dell'Insubria | 2 |
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 1 |
| Cambridge University Hospitals NHS Foundation Trust | 1 |
| Guangzhou Institute of Respiratory Disease | 1 |
| Hospital Universitario Virgen de la Arrixaca | 1 |
| King Faisal Specialist Hospital & Research Center | 1 |
| Medical University of Vienna | 1 |
| Sichuan University | 1 |
| Sixth Affiliated Hospital, Sun Yat-sen University | 1 |
| Tianjin Medical University Cancer Institute and Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Postoperative Complications | 14 |
| Hemorrhage | 2 |
| Infections | 2 |
| Anxiety Disorders | 1 |
| Atrial Fibrillation | 1 |
| Breast Neoplasms | 1 |
| Breast Neoplasms, Male | 1 |
| Cardiotoxicity | 1 |
| Colorectal Neoplasms | 1 |
| Esophageal Neoplasms | 1 |
Trials
Showing 1 to 14 of 14. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.